“First-in-Class“ mRNA-therapeutics for vascular diseases: Pantherna Therapeutics receives 7-digit investment
The life science start-up Pantherna Therapeutics secures €3.5 million [...]
Pantherna Therapeutics participated as a finalist at BioRiver Boost! 2018 in Wuppertal.
The Company was presented by Dr. Klaus Giese, Chief Executive [...]
Pantherna Therapeutics filed its first patent application “Recombinant nucleic acid construct”.
The patent filing of our ideas with confirming experimental data [...]
Pantherna Therapeutics presented at Biovaria in Munich.
Dr. Klaus Giese, Pantherna’s CEO, provided an overview of the [...]
Pantherna Therapeutics contracted with the Institute of Biomaterial Research of the Helmholtz-Zentrum Geesthacht.
Under this contract the Institute will generate and functionally evaluate [...]
Pantherna Therapeutics attended the BIO.NRW Business Angel ZIRKEL in Duesseldorf.
Dr. Gerrit Maaß, Chief Financial Officer, and Dr. Klaus Giese, [...]
Dr. Oliver Keil joined Pantherna Therapeutics as Chief Technology Officer.
Oliver is an experienced chemist with a long standing list [...]